We are currently recruiting a post-doctoral scholar with experience in mass spectrometry-based proteomics to help us advance our mission of discovering new targets and developing new immunotherapies for blood cancers.
Specifically, our group has developed new methods of profiling the cancer cell surface using mass spectrometry-based proteomics to identify immunotherapy targets and then using novel, fully in vitro-display technologies to develop nanobody binders that are highly active in cellular therapy approaches. See more details here.
We now seek a motivated post-doc to work on a new project integrating chemical biology/redox biology and mass spectrometry strategies to identify new classes of immunotherapeutic targets in cancer. Experience in redox proteomics is an advantage, as is experience in bioinformatics or computational biology. Experience in basic biological techniques such as cell culture, cloning, PCR, Western blotting, transfection/transduction, and/or cytotoxicity assays are also a plus.
We aim to apply these approaches specifically to the currently-incurable blood cancer multiple myeloma, in which our group focuses through our involvement with the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative. Notably, we have ongoing collaborations with leading protein engineering and cellular therapy groups at UCSF as well as the Parker Institute for Cancer Immunotherapy to enhance the scope and impact of this work. The goal of this work is both to make new scientific discoveries but also ultimately impact the lives of patients.
See additional details about UCSF and how to apply here.